OnKure Therapeutics (NASDAQ:OKUR) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of OnKure Therapeutics (NASDAQ:OKUR) from a hold rating to a sell rating in a research note released on Saturday.

OKUR has been the topic of a number of other research reports. Weiss Ratings upgraded shares of OnKure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, April 24th. JonesTrading lowered shares of OnKure Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday. Finally, HC Wainwright dropped their price objective on shares of OnKure Therapeutics from $34.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday, March 16th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, OnKure Therapeutics currently has an average rating of “Hold” and a consensus target price of $27.00.

OnKure Therapeutics Stock Down 1.3%

Shares of OKUR stock opened at $3.91 on Friday. The stock has a market cap of $53.45 million, a price-to-earnings ratio of -0.90 and a beta of 0.36. OnKure Therapeutics has a fifty-two week low of $1.70 and a fifty-two week high of $5.38. The firm’s 50 day moving average price is $4.10 and its two-hundred day moving average price is $3.32.

OnKure Therapeutics (NASDAQ:OKUR) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.37). On average, equities analysts forecast that OnKure Therapeutics will post -2.84 EPS for the current fiscal year.

Institutional Trading of OnKure Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in OKUR. ADAR1 Capital Management LLC bought a new stake in shares of OnKure Therapeutics in the fourth quarter worth $2,941,000. Rosalind Advisors Inc. bought a new stake in shares of OnKure Therapeutics in the fourth quarter worth $2,118,000. Shay Capital LLC increased its stake in shares of OnKure Therapeutics by 417.8% in the second quarter. Shay Capital LLC now owns 782,046 shares of the company’s stock worth $1,869,000 after buying an additional 631,008 shares during the last quarter. Prosight Management LP increased its stake in shares of OnKure Therapeutics by 204.9% in the fourth quarter. Prosight Management LP now owns 816,909 shares of the company’s stock worth $2,369,000 after buying an additional 548,950 shares during the last quarter. Finally, Kotler Kevin bought a new stake in shares of OnKure Therapeutics in the fourth quarter worth $573,000. Institutional investors own 90.98% of the company’s stock.

About OnKure Therapeutics

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.